{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicighnph7sdfou2z6lhfi4ogxh7kue4bwpsff4tz3paogpxazrm3a",
    "uri": "at://did:plc:jnrunyjrvpsiwcljmm47ycsz/app.bsky.feed.post/3mjl6sao3duz2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiceazc2pbpaji2ei2jthvjoymhufsjkohfg4eebvibguhovklqbje"
    },
    "mimeType": "image/jpeg",
    "size": 111902
  },
  "path": "/news/health/alzheimer-national-institute-for-health-and-care-excellence-netherlands-nhs-cochrane-b1278889.html",
  "publishedAt": "2026-04-16T00:00:00.000Z",
  "site": "https://www.standard.co.uk",
  "tags": [
    "Health",
    "News"
  ],
  "textContent": "A review, which included licensed drugs lecanemab and donanemab, found the effects were ‘trivial’.",
  "title": "Alzheimer’s drugs ‘make no meaningful difference to patients’, say researchers",
  "updatedAt": "2026-04-16T00:00:00.000Z"
}